We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CBA:ASXCommonwealth Bank of Australia Analysis

Data as of 2026-03-09 - not real-time

A$169.45

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Commonwealth Bank is trading just above its 20‑day simple moving average, while still lagging the 50‑day SMA, indicating limited short‑term momentum. The 14‑day RSI sits in the mid‑40s, suggesting neither overbought nor oversold conditions. A bearish MACD histogram reinforces the view that downside pressure may outweigh upside potential. The current price is sandwiched between a clear support near the low‑158 level and resistance around the high‑180 zone, leaving little room for a rally. With a 30‑day volatility above 25% and an exceptionally low beta, the stock can exhibit sharp moves despite its defensive beta profile. The forward PE is well above the industry average, and the dividend yield of just under 3% comes with a high payout ratio, raising questions about long‑term sustainability.
Recent analyst consensus has turned negative, with a “sell” rating and a median price target more than 20% below the market level. Upcoming earnings are expected to be pressured by margin compression and higher funding costs following recent RBA rate hikes. Although the bank holds a massive cash balance, operating cash flow has turned sharply negative, adding a layer of uncertainty to cash‑flow generation. The dividend announcement of A$2.35 per share reflects a commitment to return capital, but the sustainability of that payout is questionable given the cash‑flow backdrop. Sector‑specific regulatory scrutiny remains high, while the bank’s geographic exposure is concentrated in Australia, limiting currency and geopolitical risk. In this environment, the stock appears overvalued with limited upside, supporting a short‑term sell stance and a more cautious hold outlook for longer horizons.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • bearish MACD histogram
  • price near resistance with limited upside
  • negative operating cash flow

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • valuation well above industry peers
  • stable dividend yield
  • moderate revenue growth but margin pressure

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • large cash reserves offsetting debt load
  • low geographic and currency risk
  • high regulatory scrutiny could constrain earnings

Key Metrics & Analysis

Financial Health

Revenue Growth6.60%
Profit Margin36.35%
P/E Ratio27.2
ROE13.64%
ROA0.77%
P/B Ratio3.7
Op. Cash FlowA$-45702000640
Industry P/E17.4

Technical Analysis

TrendNeutral
RSI48.8
SupportA$158.47
ResistanceA$180.60
MA 20A$174.79
MA 50A$162.71
MA 200A$168.29
MACDBearish
VolumeDecreasing
Fear & Greed Index100

Valuation

Target PriceA$127.44
Upside/Downside-24.79%
GradeOvervalued
TypeValue
Dividend Yield2.92%

Risk Assessment

Beta0.14
Volatility28.58%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.